A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of hiv-1 protease

New England Journal of Medicine

Volumn 333, Issue 23, 1995, Pages 1528-1534

  Danner, Sven A ^a   Carr, Andrew ^a   Leonard, John M ^a   Lehman, Leah M ^a   Gudiol, Francesc ^a   Gonzales, Juan ^a   Raventos, Antonio ^a   Rubio, Rafael ^a   Bouza, Emilio ^a   Pintado, Vicente ^a   Aguado, Antonio Gil ^a   Garcia de Lomas, Juan ^a   Delgado, Rafael ^a   Borleffs, Jan C c ^a   Hsu, Ann ^a   Valdes, Joaquin M ^a   Boucher, Charles A b ^a   Cooper, David A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; RITONAVIR; RNA, VIRAL; THIAZOLES; TREATMENT OUTCOME; VALINE;

EID: 0028846165     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199512073332303     Document Type: Article

References (23)

1. Richman DD Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993; 37: 1207-1213
2. Kohl NE, Emini EA, Schleif WA, Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988; 85: 4686-4690
3. Debouck C The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992; 8: 153-164
4. Reedijk M, Boucher CAB, van Bommel T, The safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1995; 39: 1559-1564
5. Kitchen VS, Skinner C, Ariyoshi K, Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-955
6. Kempf DJ, Marsh KC, Denissen JF, ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 1995; 92: 2484-2488
7. Pachl C, Todd JA, Kern DG, Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 446-454
8. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S Rapid and simple PCR assay for quantification of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32: 292-300
9. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis 1994; 169: 416-419
10. Jurriaans S, Weverling GJ, Goudsmit J, Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. AIDS Res Hum Retroviruses 1995; 11: 473-479
11. Havlir D, Cheeseman SH, McLaughlin M, High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-545
12. D'Aquila RT, Johnson VA, Welles SL, Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401-408
13. Loveday C, Kaye S, Tenant-Flowers M, HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995; 345: 820-824
14. Schuurman R, Nijhuis M, van Leeuwen R, Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine. J Infect Dis 1995; 171: 1411-1419
15. Katlama C, European Lamivudine HIV Working Group. Combination 3TC/ZDV vs. ZDV monotherapy in ZDV naive HIV-1 positive patients with a CD4 of 100-400 cells/mm3. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29– February 2, 1995. Washington, D.C.: American Society of Microbiology, 1995:29. abstract.
16. Staszewski S, European Lamivudine HIV Working Group. Combination 3TC/ZDV vs. ZDV monotherapy in ZDV experienced HIV-1 positive patients with a CD4 of 100-400 cells/mm3. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29– February 2, 1995. Washington, D.C.: American Society of Microbiology, 1995:29. abstract.
17. Condra JH, Schleif WA, Blahy OM, In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-571
18. Markowitz M, Mo HM, Kempf DJ, Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995; 69: 701-706
19. Molla A, Bouche C, Korneyeva M, et al. Evolution of resistance to the protease inhibitor ritonavir (ABT-538) in HIV infected patients. Presented at the Fourth International Workshop on HIV Drug Resistance, Sardinia, Italy, July 6– 9, 1995:69. abstract.
20. Norbeck D, Hsu A, Granneman R, et al. Virologic and immunologic response to ritonavir (ABT-538), an inhibitor of HIV protease. Presented at the Fourth International Workshop on HIV Drug Resistance, Sardinia, Italy, July 6– 9, 1995:70. abstract.
21. Wei X, Ghosh SK, Taylor ME, Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122
22. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126
23. Bilello JA, Bilello PA, Stellrecht K, et al. The uptake and anti-HIV activity of A-80987, an inhibitor of the HIV-1 protease, is reduced by human serum α1-acid glycoprotein. J Clin Invest (in press).